Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 3Melanoma 3Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 282Rituximab 260Etoposide 161Filgrastim 155Vincristine 145Doxorubicin 134Prednisone 117Cytarabine 108Radiotherapy 102Peripheral Blood Stem Cell Transplantation 90Methotrexate 90fludarabine phosphate 87Melphalan 78Busulfan 71Dexamethasone 59Granulocyte Colony-Stimulating Factor 56Carmustine 53fludarabine 51Bortezomib 46Tacrolimus 44Mycophenolic Acid 41Antilymphocyte Serum 41Ifosfamide 40Leucovorin 39Gemcitabine 38Whole-Body Irradiation 36Cyclosporine 35Bendamustine Hydrochloride 34sargramostim 33Methylprednisolone 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma × sepantronium × Clear all
NCT00818480 2015-09-04

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Astellas Pharma Inc

Phase 2 Completed
10 enrolled
DermatologicGenitourinaryLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡